References
- Abu N, Akhtar MN, Yeap SK, Lim KL, Ho WY, Zulfadli AJ, Omar AR, Sulaiman MR, Abdullah MP, Alitheen NB. 2014. Flavokawain A Induces apoptosis in MCF-7 and MDA-MB231 and inhibits the metastatic process in vitro. PLoS One. 9(10):e105244.
- Ambros V. 1989. A hierarchy of regulatory genes controls a larva-to-adult developmental switch in C. elegans. Cell. 57(1):49–57. http://www.sciencedirect.com/science/article/pii/0092867489901712.
- Argast GM, Krueger JS, Thomson S, Sujka-Kwok I, Carey K, Silva S, O’Connor M, Mercado P, Mulford IJ, David Young G, et al. 2011. Inducible expression of TGFβ, Snail and Zeb1 recapitulates EMT in vitro and in vivo in a NSCLC model. Clin Exp Metastasis. 28(7):593–614. http://www.ncbi.nlm.nih.gov/pubmed/21643654.
- Balasubramaniam SL, Gopalakrishnapillai A, Gangadharan V, Duncan RL, Barwe SP. 2015. Sodium-calcium exchanger 1 regulates epithelial cell migration via calcium-dependent extracellular signal-regulated kinase signaling. J Biol Chem. 290(20):12463–12473. http://www.ncbi.nlm.nih.gov/pubmed/25770213.
- Barbieri F, Thellung S, Ratto A, Carra E, Marini V, Fucile C, Bajetto A, Pattarozzi A, Würth R, Gatti M, et al. 2015. In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors. BMC Cancer. 15(1):228.
- Bartel DP. 2009. MicroRNAs: target recognition and regulatory functions. Cell. 136(2):215–233. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3794896&tool=pmcentrez&rendertype=abstract.
- Bhola NE, Balko JM, Dugger TC, Kuba MG, Sánchez V, Sanders M, Stanford J, Cook RS, Arteaga CL. 2013. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest. 123(3):1348–1358. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3582135&tool=pmcentrez&rendertype=abstract.
- Bogachek MV, Park JM, De Andrade JP, Kulak MV, White JR, Wu T, Spanheimer PM, Bair TB, Olivier AK, Weigel RJ. 2015. A novel animal model for locally advanced breast cancer. Ann Surg Oncol. 22(3):866–873. http://www.ncbi.nlm.nih.gov/pubmed/25326397.
- Brameld KA, Owens TD, Verner E, Venetsanakos E, Bradshaw JM, Phan VT, Tam D, Leung K, Shu J, LaStant J, et al. 2017. Discovery of the irreversible covalent FGFR inhibitor 8-(3-(4-acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3- d ]pyrimidin-7(8 H)-one (PRN1371) for the treatment of solid tumors. J Med Chem. 60(15):6516–6527. http://www.ncbi.nlm.nih.gov/pubmed/28665128.
- Caceres S, Peña L, de Andres PJ, Illera MJ, Lopez MS, Woodward WA, Reuben JM, Illera JC, Samant R. 2015. Establishment and characterization of a new cell line of canine inflammatory mammary cancer: IPC-366. PLoS One. 10(3):e0122277. http://dx.plos.org/10.1371/journal.pone.0122277.
- Chekhun VF, Kulik GI, Yurchenko OV, Tryndyak VP, Todor IN, Luniv LS, Tregubova NA, Pryzimirska TV, Montgomery B, Rusetskaya NV, Pogribny IP. 2006. Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells. Cancer Lett. 231(1):87–93. http://www.sciencedirect.com/science/article/pii/S0304383505001126.
- Chen Y-C, Ingram PN, Fouladdel S, McDermott SP, Azizi E, Wicha MS, Yoon E. 2016. High-throughput single-cell derived sphere formation for cancer stem-like cell identification and analysis. Sci Reports. 6(1):1–12. https://www.nature.com/articles/srep27301.
- Chhipa RR, Singh S, Surve S V, Vijayakumar MV, Bhat MK. 2005. Doxycycline potentiates antitumor effect of cyclophosphamide in mice. Toxicol Appl Pharmacol. 202(3):268–277. http://www.ncbi.nlm.nih.gov/pubmed/15667832.
- Clements DN, Carter SD, Innes JF, Ollier WER, Day PJR. 2006. Analysis of normal and osteoarthritic canine cartilage mRNA expression by quantitative polymerase chain reaction. Arthritis Res Ther. 8(6):R158. http://www.ncbi.nlm.nih.gov/pubmed/17032449.
- Cocola C, Anastasi P, Astigiano S, Piscitelli E, Pelucchi P, Vilardo L, Bertoli G, Beccaglia M, Veronesi MC, Sanzone S, et al. 2009. Isolation of canine mammary cells with stem cell properties and tumour-initiating potential. Reprod Domest Anim. 44(Suppl 2):214–217. http://www.ncbi.nlm.nih.gov/pubmed/19754572.
- Cullen JM, Matthew B. 2002. An overview of cancer pathogenesis, diagnosis and management. In: Meuten DJ, editor. Tumors in domestic animals. Blackwell Publishing Company, Ames, Iowa State Press; p. 3–45.
- Emmink BL, Verheem A, Van Houdt WJ, Steller EJA, Govaert KM, Pham TV, Piersma SR, Borel Rinkes IHM, Jimenez CR, Kranenburg O. 2013. The secretome of colon cancer stem cells contains drug-metabolizing enzymes. J Proteomics. 91:84–96. http://linkinghub.elsevier.com/retrieve/pii/S1874391913003734.
- Ferletta M, Grawé J, Hellmén E. 2011. Canine mammary tumors contain cancer stem-like cells and form spheroids with an embryonic stem cell signature. Int J Dev Biol. 55(7–9):791–799. http://www.ijdb.ehu.es/web/descarga/paper/113363mf.
- Ferraresso S, Bresolin S, Aricò A, Comazzi S, Gelain ME, Riondato F, Bargelloni L, Marconato L, Kronnie GT, Aresu L, Mills K. 2014. Epigenetic silencing of TFPI-2 in canine diffuse large B-cell lymphoma. PLoS One. 9(4):e92707. http://www.ncbi.nlm.nih.gov/pubmed/24695110.
- Fish EJ, Martinez-Romero EG, DeInnocentes P, Koehler JW, Prasad N, Smith AN, Bird RC. 2020. Circulating microRNA as biomarkers of canine mammary carcinoma in dogs. J Vet Intern Med. 34(3):1282–1290.
- Foong JN, Selvarajah GT, Rasedee A, Rahman HS, How CW, Beh CY, Teo GY, Ku CL. 2018. Zerumbone-loaded nanostructured lipid carrier induces apoptosis of canine mammary adenocarcinoma cells. Biomed Res Int. 2018:1–18.
- Gartzke D, Delzer J, Laplanche L, Uchida Y, Hoshi Y, Tachikawa M, Terasaki T, Sydor J, Fricker G. 2015. Genomic knockout of endogenous canine P-glycoprotein in wild-type, human P-glycoprotein and human BCRP transfected MDCKII cell lines by zinc finger nucleases. Pharm Res. 32(6):2060–2071. http://www.ncbi.nlm.nih.gov/pubmed/25522789.
- Goldschmidt M, Peña L, Rasotto R, Zappulli V. 2011. Classification and grading of canine mammary tumors. Vet Pathol. 48(1):117–131. http://www.ncbi.nlm.nih.gov/pubmed/21266722.
- Gorovetz M, Schwob O, Krimsky M, Yedgar S, Reich R. 2008. MMP production in human fibrosarcoma cells and their invasiveness are regulated by group IB secretory phospholipase A2 receptor-mediated activation of cytosolic phospholipase A2. Front Biosci. 13:1917–1925. http://www.ncbi.nlm.nih.gov/pubmed/17981679.
- Gottesman MM. 2002. Mechanisms of cancer drug resistance. Annu Rev Med. 53:615–627. http://www.annualreviews.org/doi/abs/10.1146/annurev.med.53.082901.103929?journalCode=med.
- Gottesman MM, Fojo T, Bates SE. 2002. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2(1):48–58. doi:10.1038/nrc706.
- Hocker SE, Higginbotham ML, Schermerhorn T, Henningson J. 2017. Receptor tyrosine kinase expression and phosphorylation in canine nasal carcinoma. Res Vet Sci. 115:484–489. http://linkinghub.elsevier.com/retrieve/pii/S0034528817303880.
- Honscha KU, Schirmer A, Reischauer A, Schoon H-A, Einspanier A, Gäbel G. 2009. Expression of ABC-transport proteins in canine mammary cancer: consequences for chemotherapy. Reprod Domest Anim. 44(Suppl 2):218–223. http://www.ncbi.nlm.nih.gov/pubmed/19754573.
- Hou Y, Li W, Sheng Y, Li L, Huang Y, Zhang Z, Zhu T, Peace D, Quigley JG, Wu W, et al. 2015. The transcription factor Foxm1 is essential for the quiescence and maintenance of hematopoietic stem cells. Nat Immunol. 16(8):810–818. http://www.ncbi.nlm.nih.gov/pubmed/26147687.
- Huang X, Huang L, Shao M. 2017. Aquaporin 3 facilitates tumor growth in pancreatic cancer by modulating mTOR signaling. Biochem Biophys Res Commun. 486(4):1097–1102. https://linkinghub.elsevier.com/retrieve/pii/S0006291X17306551.
- Huang X, Le Q-T, Giaccia AJ. 2010. MiR-210 – micromanager of the hypoxia pathway. Trends Mol Med. 16(5):230–237. http://linkinghub.elsevier.com/retrieve/pii/S147149141000047X.
- Hurst NJ, Najy AJ, Ustach C V, Movilla L, Kim H-RC. 2012. Platelet-derived growth factor-C (PDGF-C) activation by serine proteases: implications for breast cancer progression. Biochem J. 441(3):909–918. http://www.ncbi.nlm.nih.gov/pubmed/22035541%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3342761.
- Jansson MD, Lund AH. 2012. MicroRNA and cancer. Mol Oncol. 6(6):590–610. http://www.ncbi.nlm.nih.gov/pubmed/23102669.
- Jung E-J, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, Di Leo A, Le X-F, Bast RC, Park S-T, et al. 2012. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer. 118(10):2603–2614. doi:10.1002/cncr.26565.
- Kim B, Stephen SL, Hanby AM, Horgan K, Perry SL, Richardson J, Roundhill EA, Valleley EMA, Verghese ET, Williams BJ, et al. 2015. Chemotherapy induces Notch1-dependent MRP1 up-regulation, inhibition of which sensitizes breast cancer cells to chemotherapy. BMC Cancer. 15(1):634. http://www.biomedcentral.com/1471-2407/15/634.
- Kleylein-Sohn J, Westendorf J, Le Clech M, Habedanck R, Stierhof Y-D, Nigg EA. 2007. Plk4-induced centriole biogenesis in human cells. Dev Cell. 13(2):190–202. http://linkinghub.elsevier.com/retrieve/pii/S1534580707002638.
- Komarova NL, Wodarz D. 2005. Drug resistance in cancer: principles of emergence and prevention. Proc Natl Acad Sci U S A. 102(27):9714–9719. http://www.pnas.org/content/102/27/9714.full.
- Lee J-L, Chang C-J, Chueh L-L, Lin C-T. 2003. Expression of secreted frizzled-related protein 2 in a primary canine mammary tumor cell line: a candidate tumor marker for mammary tumor cells. In Vitro Cell Dev Biol Anim. 39(5–6):221–227. http://www.ncbi.nlm.nih.gov/pubmed/12866949.
- Lee J-L, Chang C-J, Chueh L-L, Lin C-T. 2006. Secreted frizzled related protein 2 (sFRP2) decreases susceptibility to UV-induced apoptosis in primary culture of canine mammary gland tumors by NF-κB activation or JNK suppression. Breast Cancer Res Treat. 100(1):49–58. http://www.ncbi.nlm.nih.gov/pubmed/16791480.
- Lehmann C, Jobs G, Thomas M, Burtscher H, Kubbies M. 2012. Established breast cancer stem cell markers do not correlate with in vivo tumorigenicity of tumor-initiating cells. Int J Oncol. 41(6):1932–1942.
- Li W, Chang J, Wang S, Liu X, Peng J, Huang D, Sun M, Chen Z, Zhang W, Guo W, Li J. 2015. miRNA-99b-5p suppresses liver metastasis of colorectal cancer by down-regulating mTOR. Oncotarget. 6(27):24448–24462. http://www.ncbi.nlm.nih.gov/pubmed/26259252.
- Lippert TH, Ruoff H-J, Volm M. 2008. Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure. Arzneimittelforschung. 58(6):261–264. http://www.ncbi.nlm.nih.gov/pubmed/18677966.
- Liu S, Patel SH, Ginestier C, Ibarra I, Martin-Trevino R, Bai S, McDermott SP, Shang L, Ke J, Ou SJ, et al. 2012. MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells. PLoS Genet. 8(6):e1002751. http://www.ncbi.nlm.nih.gov/pubmed/22685420.
- Liu Z, Gersbach E, Zhang X, Xu X, Dong R, Lee P, Liu J, Kong B, Shao C, Wei J-J. 2013. miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma. Mol Cancer Res. 11(11):1314–1325. http://www.ncbi.nlm.nih.gov/pubmed/24045973.
- Longley DB, Allen WL, Johnston PG. 2006. Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim Biophys Acta – Rev Cancer. 1766(2):184–196.
- Marech I, Patruno R, Zizzo N, Gadaleta C, Introna M, Zito AF, Gadaleta CD, Ranieri G. 2014. Masitinib (AB1010), from canine tumor model to human clinical development: where we are? Crit Rev Oncol Hematol. 91(1):98–111. https://www.sciencedirect.com/science/article/pii/S1040842813002667?via%3Dihub.
- Martin HL, Smith L, Tomlinson DC. 2014. Multidrug-resistant breast cancer: current perspectives. Breast Cancer (Dove Med Press). 6:1–13. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3929252&tool=pmcentrez&rendertype=abstract.
- Mathias RA, Chen Y-S, Wang B, Ji H, Kapp EA, Moritz RL, Zhu H-J, Simpson RJ. 2010. Extracellular remodelling during oncogenic Ras-induced epithelial-mesenchymal transition facilitates MDCK cell migration. J Proteome Res. 9(2):1007–1019. http://www.ncbi.nlm.nih.gov/pubmed/19954229.
- Meier V, Guscetti F, Roos M, Ohlerth S, Pruschy M, Bley CR. 2016. Hypoxia-related marker glut-1, caix, proliferative index and microvessel density in canine oral malignant neoplasia. PLoS One. 11(2):e0149993. http://www.ncbi.nlm.nih.gov/pubmed/26906567.
- Michishita M, Akiyoshi R, Suemizu H, Nakagawa T, Sasaki N, Takemitsu H, Arai T, Takahashi K. 2012. Aldehyde dehydrogenase activity in cancer stem cells from canine mammary carcinoma cell lines. Vet J. 193(2):508–513.
- Mohammadi-Yeganeh S, Paryan M, Arefian E, Vasei M, Ghanbarian H, Mahdian R, Karimipoor M, Soleimani M. 2016. MicroRNA-340 inhibits the migration, invasion, and metastasis of breast cancer cells by targeting Wnt pathway. Tumour Biol. 37(7):8993–9000. http://www.ncbi.nlm.nih.gov/pubmed/26758430.
- Moitra K. 2015. Overcoming multidrug resistance in cancer stem cells. Biomed Res Int. 2015:1–8. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4663294&tool=pmcentrez&rendertype=abstract.
- Molina-Pinelo S, Carnero A, Rivera F, Estevez-Garcia P, Bozada JM, Limon ML, Benavent M, Gomez J, Pastor MD, Chaves M, et al. 2014. MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer. BMC Cancer. 14:656. http://www.ncbi.nlm.nih.gov/pubmed/25197016.
- Morris JS. 2016. Genomic and proteomic profiling for cancer diagnosis in dogs. Vet J. 215:101–109. http://www.sciencedirect.com/science/article/pii/S1090023316000046.
- National Research Council. 2011. Guide for the care and use of laboratory animals. Washington, DC: National Academies Press. p. 267–268. http://www.ncbi.nlm.nih.gov/pubmed/21595115.
- Nerurkar VR, Chitale AR, Jalnapurkar BV, Naik SN, Lalitha VS. 1989. Comparative pathology of canine mammary tumours. J Comp Pathol. 101(4):389–397.
- Oliveros JC. 2016. Venny. An interactive tool for comparing lists with Venn’s diagrams. https://bioinfogp.cnb.csic.es/tools/venny/index.html.
- Oosterwijk E, Gillies RJ. 2014. Targeting ion transport in cancer. Philos Trans R Soc Lond B Biol Sci. 369(1638):20130107. http://www.ncbi.nlm.nih.gov/pubmed/24493755.
- Pang LY, Cervantes-Arias A, Else RW, Argyle DJ. 2011. Canine mammary cancer stem cells are radio- and chemo- resistant and exhibit an epithelial-mesenchymal transition phenotype. Cancers (Basel). 3(2):1744–1762.
- Pang LY, Gatenby EL, Kamida A, Whitelaw BA, Hupp TR, Argyle DJ. 2014. Global gene expression analysis of canine osteosarcoma stem cells reveals a novel role for COX-2 in tumour initiation. PLoS One. 9(1):e83144. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3885401&tool=pmcentrez&rendertype=abstract.
- Pastrana E, Silva-Vargas V, Doetsch F. 2011. Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell. 8(5):486–498.
- Piva R, Spandidos DA, Gambari R. 2013. From microRNA functions to microRNA therapeutics: novel targets and novel drugs in breast cancer research and treatment. Int J Oncol. 43(4):985–994. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3829774&tool=pmcentrez&rendertype=abstract.
- Prasad V, Suomalainen M, Pennauer M, Yakimovich A, Andriasyan V, Hemmi S, Greber UF. 2014. Chemical induction of unfolded protein response enhances cancer cell killing through lytic virus infection. J Virol. 88(22):13086–13098. http://www.ncbi.nlm.nih.gov/pubmed/25187554.
- Qin W, Ren Q, Liu T, Huang Y, Wang J. 2013. MicroRNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets CLDN1. FEBS Lett. 587(9):1434–1439. doi:10.1016/j.febslet.2013.03.023.
- Qiu T, Xiang X, Lei W, Hao C, Zhang L, Feng M, Yu F, Li J, Xiong J. 2015. Establishment and biological characterization of 5-fluorouracil-resistant human colon cancer HT-29/5-FU cell line. Chinese J Cell Mol Immunol. 31(3):328–332. http://www.ncbi.nlm.nih.gov/pubmed/25744837.
- Queiroga FL, Raposo T, Carvalho MI, Prada J, Pires I. 2011. Canine mammary tumours as a model to study human breast cancer: most recent findings. In Vivo. 25(3):455–465.
- Rahman MM, Lai Y-C, Husna AA, Chen H, Tanaka Y, Kawaguchi H, Miyoshi N, Nakagawa T, Fukushima R, Miura N. 2019. Micro RNA transcriptome profile in canine oral melanoma. Int J Mol Sci. 20(19):4832. https://www.mdpi.com/1422-0067/20/19/4832.
- Rai SS, Wolff J. 1996. Localization of the vinblastine-binding site on β-tubulin. J Biol Chem. 271(25):14707–14711. http://www.ncbi.nlm.nih.gov/pubmed/8663038.
- Rothschild SI. 2014. microRNA therapies in cancer. Mol Cell Ther. 2(1):7. http://www.molcelltherapies.com/content/2/1/7.
- Rybicka A, Eyileten C, Taciak B, Mucha J, Majchrzak K, Hellmen E, Krol M. 2016. Tumour-associated macrophages influence canine mammary cancer stem-like cells enhancing their pro-angiogenic properties. J Physiol Pharmacol. 67(4):491–500. http://www.ncbi.nlm.nih.gov/pubmed/27779470.
- Rybicka A, Mucha J, Majchrzak K, Taciak B, Hellmen E, Motyl T, Krol M. 2015. Analysis of microRNA expression in canine mammary cancer stem-like cells indicates epigenetic regulation of transforming growth factor-beta signaling. J Physiol Pharmacol. 66(1):29–37. http://www.ncbi.nlm.nih.gov/pubmed/25716962.
- Saijo N. 2012. Critical comments for roles of biomarkers in the diagnosis and treatment of cancer. Cancer Treat Rev. 38(1):63–67. http://www.ncbi.nlm.nih.gov/pubmed/21652149.
- Salgado BS, Nonogaki S, Soares LM, Akamatsu A, da Silva CRN, Anacleto TP, Malagó R, Rocha RM, Gärtner F, Rocha NS 2015. Expression of multidrug resistance ATP-binding cassette (ABC) transporters in canine mammary tumors. Adv Breast Cancer Res. 04(03):77–85. http://www.scirp.org/journal/PaperInformation.aspx?PaperID=58406&#abstract.
- Sanders AM, Stehle JR, Blanks MJ, Riedlinger G, Kim-Shapiro JW, Monjazeb AM, Adams JM, Willingham MC, Cui Z. 2010. Cancer resistance of SR/CR mice in the genetic knockout backgrounds of leukocyte effector mechanisms: determinations for functional requirements. BMC Cancer. 10(1):121. http://www.ncbi.nlm.nih.gov/pubmed/20356394.
- Santos A, Lopes C, Marques RM, Amorim I, Ribeiro J, Frias C, Vicente C, Gärtner F, de Matos A. 2011. Immunohistochemical analysis of urokinase plasminogen activator and its prognostic value in canine mammary tumours. Vet J. 189(1):43–48. http://linkinghub.elsevier.com/retrieve/pii/S1090023310001863.
- Schultz NA, Dehlendorff C, Jensen BV, Bjerregaard JK, Nielsen KR, Bojesen SE, Calatayud D, Nielsen SE, Yilmaz M, Holländer NH, et al. 2014. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA. 311(4):392–404. http://www.ncbi.nlm.nih.gov/pubmed/24449318.
- Selvarajah GT. 2011. Comparative studies on prognostic markers and signaling pathways for canine and human osteosarcoma. http://dspace.library.uu.nl/handle/1874/202742.
- Selvarajah GT, Kirpensteijn J, van Wolferen ME, Rao NAS, Fieten H, Mol JA. 2009. Gene expression profiling of canine osteosarcoma reveals genes associated with short and long survival times. Mol Cancer. 8(72):1–18.
- Selvarajah GT, Verheije MH, Kik M, Slob A, Rottier PJM, Mol JA, Kirpensteijn J. 2012. Expression of epidermal growth factor receptor in canine osteosarcoma: association with clinicopathological parameters and prognosis. Vet J. 193(2012):412–419.
- Sharpe R, Pearson A, Herrera-Abreu MT, Johnson D, Mackay A, Welti JC, Natrajan R, Reynolds AR, Reis-Filho JS, Ashworth A, Turner NC. 2011. FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res. 17(16):5275–5286. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3432447&tool=pmcentrez&rendertype=abstract.
- Shen F, Chu S, Bence AK, Bailey B, Xue X, Erickson PA, Montrose MH, Beck WT, Erickson LC. 2008. Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J Pharmacol Exp Ther. 324(1):95–102. http://jpet.aspetjournals.org/cgi/doi/10.1124/jpet.107.127704.
- Sipila PEH, Wiebe VJ, Hubbard GB, Koester SK, Emshoff VD, Maenpaa JU, Wurz GT, Seymour RC, DeGregorio MW. 1993. Prolonged tamoxifen exposure selects a breast cancer cell clone that is stable in vitro and in vivo. Eur J Cancer. 29(15):2138–2144.
- Sulakhe SJ, Lautt WW. 1987. A characterization of gamma-glutamyltranspeptidase in normal, perinatal, premalignant and malignant rat liver. Int J Biochem. 19(1):23–32. http://www.ncbi.nlm.nih.gov/pubmed/2883036.
- Tanaka T, Iino M. 2014. Knockdown of Sec8 promotes cell-cycle arrest at G1/S phase by inducing p21 via control of FOXO proteins. FEBS J. 281(4):1068–1084. http://www.ncbi.nlm.nih.gov/pubmed/24299491.
- Tang R, Yang C, Ma X, Wang Y, Luo D, Huang C, Xu Z, Liu P, Yang L. 2016. MiR-let-7a inhibits cell proliferation, migration, and invasion by down-regulating PKM2 in gastric cancer. Oncotarget. 7(5):5972–5984. http://www.ncbi.nlm.nih.gov/pubmed/26745603.
- Tegze B, Szállási Z, Haltrich I, Pénzváltó Z, Tóth Z, Likó I, Gyorffy B. 2012. Parallel evolution under chemotherapy pressure in 29 breast cancer cell lines results in dissimilar mechanisms of resistance. PLoS One. 7(2):e30804.
- Tomiyasu H, Goto-koshino Y, Fujino Y, Ohno K, Tsujimoto H. 2014. Epigenetic regulation of the ABCB1 gene in drug-sensitive and drug-resistant lymphoid tumour cell lines obtained from canine patients. Vet J. 199:103–109.
- Tomiyasu H, Goto-Koshino Y, Takahashi M, Fujino Y, Ohno K, Tsujimoto H. 2010. Quantitative analysis of mRNA for 10 different drug resistance factors in dogs with lymphoma. J Vet Med Sci. 72(9):1165–1172.
- Volinia S, Calin GA, Liu C-G, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al. 2006. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 103(7):2257–2261. http://www.ncbi.nlm.nih.gov/pubmed/16461460.
- Wang L, Chang L, Li Z, Gao Q, Cai D, Tian Y, Zeng L. 2014. miR-99a and -99b inhibit cervical cancer cell proliferation and invasion by targeting mTOR signaling pathway. Med Oncol. 31(5):934. http://www.ncbi.nlm.nih.gov/pubmed/24668416.
- Wu Q, Yang Z, Wang F, Hu S, Yang L, Shi Y, Fan D. 2013. MiR-19b/20a/92a regulates the self-renewal and proliferation of gastric cancer stem cells. J Cell Sci. 126(18):4220–4229. http://www.ncbi.nlm.nih.gov/pubmed/23868977.
- Yamauchi A, Kontani K, Kihara M, Nishi N, Yokomise H, Hirashima M. 2006. Galectin-9, a novel prognostic factor with antimetastatic potential in breast cancer. Breast J. 12(s2):S196–S200. http://www.ncbi.nlm.nih.gov/pubmed/16959001.
- Yang S, Zhang L, Purohit V, Shukla SK, Chen X, Yu F, Fu K, Chen Y, Solheim J, Singh PK, et al. 2015. Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3. Oncotarget. 6(34):36019–36031. http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=5935&path%5B%5D=14241.
- Yang X. 2012. Clonogenic assay. Bio Protoc. 20(10):2–3. http://www.bio-protocol.org/e187.
- Zadran S, Remacle F, Levine RD. 2013. miRNA and mRNA cancer signatures determined by analysis of expression levels in large cohorts of patients. Proc Natl Acad Sci U S A. 110(47):19160–19165. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3839764&tool=pmcentrez&rendertype=abstract.
- Zhang B, Zhao R, He Y, Fu X, Fu L, Zhu Z, Fu L, Dong J-T. 2015. Micro RNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR. Oncotarget. 7(5):5702–5714. http://www.ncbi.nlm.nih.gov/pubmed/26744318.
- Zhou B, Jin Y, Zhang D, Lin D. 2018. 5-Fluorouracil may enrich cancer stem cells in canine mammary tumor cells in vitro. Oncol Lett. 15(5):7987–7992. http://www.spandidos-publications.com/10.3892/ol.2018.8267.
- Zhou B, Zhang D, Pei SM, Zhang H, Du HC, Jin YP, Lin DG. 2017. Establishment of 5-fluorouracil-resistant canine mammary tumor cell line. Pol J Vet Sci. 20(1):103–110. http://www.degruyter.com/view/j/pjvs.2017.20.issue-1/pjvs-2017-0014/pjvs-2017-0014.xml.
- Zhou X, Wang G, Sun Y. 2015. A reliable parameter to standardize the scoring of stem cell spheres. PLoS One. 10(5):e0127348. http://www.jxedu.gov.cn.
- Zhu B, Zhang P, Zeng P, Huang Z, Dong T-F, Gui Y-K, Zhang G-W. 2013. Tissue factor pathway inhibitor-2 silencing promotes hepatocellular carcinoma cell invasion In Vitro. Anat Rec. 296(11):1708–1716. http://www.ncbi.nlm.nih.gov/pubmed/24591127.